Get all your news in one place.

100's of premium titles.
One app.

Get all your news in one place.

100's of premium titles. One news app.

FORGOTTEN HISTORY: Daiichi sankyo org - The Untold Story

NCLAT quashes Ligare Aviation's insolvency; loan from Religare Enterprises round-tripping of money

The National Company Law Appellate Tribunal has cancelled insolvency proceedings against Ligare Aviation. The tribunal found the National Company Law Tribunal wrongly admitted a plea from Religare Enterprises. It stated the transactions were merely money laundering, not genuine financial dealings. This decision allows appeals from shareholder Daiichi Sankyo Company. The…

The Economic Times

Women dying of breast cancer as life-extending drug remains blocked in England

A campaign is calling for Enhertu to be made available on the NHS.

Evening Standard

AstraZeneca/Daiichi Sankyo Partnered Breast Cancer Drug Shows Survival Benefit Over Chemotherapy

AstraZeneca Plc (NASDAQ:AZN) and Daiichi Sankyo on Monday released high-level results from the TROPION-Breast02 Phase 3 trial.

Benzinga

From analysis to the latest developments in health,
read the most diverse news in one place.

Breast cancer drug blocked for NHS use in England and Wales after talks collapse

National Institute for Health and Care Excellence unable to reach price agreement with manufacturers of Enhertu

The Guardian - UK

Breast cancer drug blocked for NHS use as price talks break down – leaving charities ‘beyond devastated’

Nice said it was ‘extremely disappointed’ it will be unable to recommend trastuzumab deruxtecan, sold under the brand name Enhertu

The Independent UK

Breast cancer drug blocked for NHS use as price talks break down for third time

Nice said it was ‘extremely disappointed’ it will be unable to recommend trastuzumab deruxtecan, sold under the brand name Enhertu.

Evening Standard

3 Healthcare Stocks Positioned for Major Gains in 2024

With advancements in biomedical sciences and promising drug pipelines, the healthcare industry is set for substantial growth in the coming years. Hence, investors might find opportunities in adding UnitedHealth Group (UNH), Merck & Co. (MRK), and Pfizer (PFE) to their portfolios for potential gains this year. Read on….

StockNews.com

Read news from The Economist, FT, and more,
with one subscription

1 Biopharma Stock Setting the New Standard in Cancer Care Drugs

The annual conference of the American Society of Clinical Oncology is always the biggest event-making cancer conference. And this year, the attention-grabber was AstraZeneca, as its lung and breast cancer drugs significantly slowed the spread of disease in two trials, potentially establishing the medicines as the new standard of care…

Barchart

Urgent call for breast cancer drug to stop women’s lives being cut short

Women with HER2-low incurable secondary disease in Scotland currently have access, while others across the UK do not

The Independent UK

Forget Weight-Loss Drugs, Here's the Next Breakthrough Pharma Stock

There is another segment of the pharma industry that is as hot as weight-loss drugs: antibody-drug conjugates, or ADCs. These treatments will, in the near future, replace conventional chemotherapy, thanks to fewer side effects for patients. Even a partial replacement for chemotherapy could make it a $140 billion market -…

Barchart

New breast cancer treatment not approved for NHS use

The health spending watchdog said the ‘the cost-effectiveness estimates were too high for it to be recommended for use in the NHS’.

The Independent UK

AstraZeneca stock value falls by nearly £14bn after cancer drug trial results

Shares close down 8% on concerns that new lung cancer drug may not be as successful as hoped

The Guardian - UK

Recap Of Friday's Biotech Catalysts - End Of the Day Summary

Pfizer (NYSE:PFE) announced positive top-line results from its pivotal U.S. Phase 3 study in infants evaluating its 20-valent pneumococcal conjugate vaccine candidate (20vPnC) for the prevention of invasive pneumococcal disease (IPD). The study met two co-primary objectives, associated with immunogenicity responses. Pfizer shares traded in a range of $48.55 to…

Benzinga

The Daily Biotech Pulse: FDA Tentatively Approves Avadel's Narcolepsy Drug, European Approval Broadens AstraZeneca's Enhertu in Breast Cancer, Pharma Giants' Earnings

Here's a roundup of top developments in the biotech space over the last 24 hours:

Benzinga

Get all your
news in one place.

100's of premium titles.
One news app.

Chicago Sun-Times

For some with breast cancer, the drug Enhertu could mean living longer, researchers report

Though not a cure, the findings announced in Chicago mark the first time a drug targeting a protein that drives breast cancer growth is shown to work against tumors with very low levels of the protein.

Benzinga

FDA Approval For AstraZeneca - Daiichi's Enhertu Expands To Earlier Use In Metastatic Breast Cancer

The FDA has approved AstraZeneca plc (NASDAQ:AZN) and Daiichi Sankyo's (OTC:DSKYF) Enhertu (trastuzumab deruxtecan) for adult patients with unresectable or metastatic HER2-positive breast cancer. The approval covers patients who have received a prior anti-HER2-based regimen either in the metastatic setting or in the neoadjuvant or adjuvant setting and have developed disease recurrence during or within…

Benzinga

Daiichi Sankyo - AstraZeneca's Enhertu Receives Third Breakthrough Therapy Tag In Breast Cancer

The FDA has granted Breakthrough Therapy Designation (BTD) to Daiichi Sankyo (OTC:DSKYF) and AstraZeneca Plc's (NASDAQ:AZN) Enhertu (fam-trastuzumab deruxtecan-nxki) for unresectable or metastatic HER2 low (IHC 1+ or IHC 2+/ISH-negative) breast cancer. The designation covers patients who have received a prior systemic therapy in the metastatic setting or developed disease recurrence during or within six months…

People

From analysis to the latest developments in health,
read the most diverse news in one place.

Organisations

Read news from The Economist, FT, and more,
with one subscription

Topics

Places

Fourteen days free

Download the app

One app. One membership.
100+ trusted global sources.